Eligard®: Pharmacokinetics, Effect on Testosterone and PSA Levels and Tolerability  Richard Berges  European Urology Supplements  Volume 4, Issue 5, Pages 20-25 (July 2005) DOI: 10.1016/j.eursup.2005.04.001 Copyright © 2005 Terms and Conditions

Fig. 1 Mean (SEM) serum testosterone levels during 6 months of Eligard® 7.5mg injections (injections days 0, 28, 56, 84, 112 and 140) [20]. Reproduced with permission from Perez-Marreno R, Tyler RC. A subcutaneous delivery system for the extended release of leuprolide acetate for the treatment of prostate cancer. Expert Opin Pharmacother 2004;5(2):447–457. Copyright © 2004 Ashley Publications Ltd. All rights reserved. European Urology Supplements 2005 4, 20-25DOI: (10.1016/j.eursup.2005.04.001) Copyright © 2005 Terms and Conditions

Fig. 2 Increase in percentage of patients with normal PSA levels following treatment with Eligard® 7.5mg; B: Baseline [18]. European Urology Supplements 2005 4, 20-25DOI: (10.1016/j.eursup.2005.04.001) Copyright © 2005 Terms and Conditions

Fig. 3 Mean (SEM) serum testosterone levels during 6 months of Eligard® 22.5mg injections (injections day 0 and 84) [20]. Reproduced with permission from Perez-Marreno R, Tyler RC. A subcutaneous delivery system for the extended release of leuprolide acetate for the treatment of prostate cancer. Expert Opin Pharmacother 2004;5(2):447–457. Copyright © 2004 Ashley Publications Ltd. All rights reserved. European Urology Supplements 2005 4, 20-25DOI: (10.1016/j.eursup.2005.04.001) Copyright © 2005 Terms and Conditions